Minor adverse events not leading to withdrawal of treatment · bacterial folliculitis and boils (furuncles and carbuncles)
1 finding from 1 review
no estimate extracted
391 participants
GRADE not reported
Minor adverse events not leading to withdrawal of treatment · bacterial folliculitis and boils (furuncles and carbuncles)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: death ‐ at end of treatment (Analysis 1.14) · people with stroke
It is very uncertain whether psychological therapy changes adverse events: death ‐ at end of treatment (Analysis 2.16) compared with usual care and/or attention control (very low certainty).
1 finding from 1 review
Serious adverse events ‐ mild to moderate disease (16 weeks) · IBD patients
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review
Serious adverse events ‐ remission or mild disease (8 weeks) · IBD patients
It is very uncertain whether IV iron isomaltoside changes serious adverse events ‐ remission or mild disease (8 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review
Serious adverse events ‐ mild to moderate disease (16 weeks) · IBD patients
It is very uncertain whether IV iron sucrose changes serious adverse events ‐ mild to moderate disease (20 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review
Serious adverse events ‐ mild to moderate disease (12 weeks) · IBD patients
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (12 weeks) compared with IV iron sucrose (very low certainty).
1 finding from 1 review
Minor adverse events not leading to withdrawal of treatment · people with atopic dermatitis
1 finding from 1 review
Minor adverse events not leading to withdrawal of treatment · people with atopic dermatitis
Bleach bath showed no clear difference in minor adverse events not requiring withdrawal from treatment compared with placebo or bath emollient (low certainty).
1 finding from 1 review
Minor adverse events not leading to withdrawal of treatment · people with eczema
It is very uncertain whether topical steroid plus topical antibiotic changes minor adverse events not requiring withdrawal from treatment compared with topical steroid (very low certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · people with a primary brain tumour
1 finding from 1 review
Harms · Indigenous children aged < 5 years
1 finding from 1 review
Serious adverse events ‐ active or inactive disease (14 days) · IBD patients
It is very uncertain whether oral iron sulphate changes serious adverse events ‐ active or inactive disease (14 days) compared with oral iron hydroxide polymaltose complex (very low certainty).
1 finding from 1 review
Primary: adverse events ‐ burning/itching at application site · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
Topical calcineurin inhibitors: tacrolimus 0.1% ointment showed no clear difference in primary: adverse events ‐ burning/itching at application site compared with vehicle (moderate certainty).
1 finding from 1 review
Serious adverse events (dichotomous data) ‐ serious infection · critically ill patients
Corticosteroids showed no clear difference in serious adverse events (dichotomous data) ‐ serious infection compared with placebo compared (high certainty).
1 finding from 1 review
Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
1 finding from 1 review
Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
It is very uncertain whether psychological therapy changes adverse events: death ‐ at end of treatment (secondary outcome) compared with usual care and/or attention control (very low certainty).
1 finding from 1 review
Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
1 finding from 1 review
Serious adverse events (excluding deaths) at 26 weeks · adult patients after liver transplantation.
1 finding from 1 review
Serious adverse events ‐ disease activity not stated (12 weeks) · IBD patients
1 finding from 1 review